Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported a series of transactions involving the exercise of stock options and the sale of common stock on June 29, 2026.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp, engaged in transactions on June 29, 2026.
• These transactions included the exercise of 9,500 stock options at a price of $135.42 per share, resulting in the acquisition of 9,500 shares of common stock.
• Following the exercise, 120, 360, 80, 585, 1,594, 2,165, 1,705, 759, 1,702, and 430 shares of common stock were sold at various weighted average prices ranging from $539.47 to $549.17.
• These sales were conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 40,513 shares directly, with additional shares held indirectly through a spouse, and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it details routine insider transactions conducted under a pre-established 10b5-1 plan, which is a standard practice for executives.

Positives

• The exercise of stock options and subsequent sale of shares were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to managing personal holdings.
• The plan allows for continued management of holdings until a significant portion of options are exercised or a set date, suggesting ongoing strategic management of executive compensation.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market if not contextualized by the 10b5-1 plan.
• The weighted average sale price of $539.9783 to $549.17 indicates a substantial value realized from the sale of shares.

Risks

• The 10b5-1 trading plan has an expiration date of December 31, 2026, or upon exercise of 1,734,410 stock options, creating a potential timeframe for future significant selling activity.
• The reporting person's beneficial ownership is spread across direct holdings, spouse's holdings, and multiple trusts, which could introduce complexity in tracking and understanding ultimate beneficial ownership.

Future Outlook

The 10b5-1 trading plan is active until December 31, 2026, or until 1,734,410 stock options are exercised, indicating potential for further transactions within this period.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions. The use of a 10b5-1 plan by a CEO of a biotechnology company like United Therapeutics is common for managing equity compensation and diversifying holdings in a pre-planned manner, mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may lead to short-term market perception shifts. However, the pre-planned nature of the sales aims to reduce adverse impact.
• Employees: The transactions reflect the executive's compensation structure and do not directly impact day-to-day employee operations.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continue to monitor insider transactions for any further activity under the 10b5-1 plan.
• Observe the company's stock performance and strategic developments in light of executive compensation management.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Common Stock, Beneficial Ownership, 10b5-1 Plan, Insider Trading, Executive Compensation, Martine Rothblatt